China, AstraZeneca
AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...
The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...
AstraZeneca restructures its China operations following leadership scandals and sales challenges, appointing new executives ...
From accelerating drug development and clinical trials to supercharging collaboration, machine learning-enhanced healthcare ...
The Food and Drug Administration approved the drug for patients with advanced breast tumors whose cells bear a certain ...
News Medical on MSN2d
AstraZeneca's Pioneering Research in Heart Failure and ATTR-CM: An interview with Mina MakerMina Makar highlights AstraZeneca's commitment to advancing heart failure research and innovative therapies, addressing ...
AstraZeneca’s share price has fallen a long way from its record-breaking level last year, which indicates that I may be ...
Shares of AstraZeneca PLC AZN rallied 1.84% to £108.44 Thursday, on what proved to be an all-around positive trading session ...
Amgen’s Lumakras and AstraZeneca’s Calquence are both in line to expand their respective oncology reaches with new FDA ...
Calquence in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients ...
GlobalData on MSN3d
JP Morgan 2025: AstraZeneca promises a ‘catalyst-rich’ year aheadCFO Aradhana Sarin outlined AstraZeneca’s plans at the 2025 JP Morgan Healthcare Conference in San Francisco on 15 January.
It’s a sobering statistic: 1 in 8 women in the United States will be diagnosed with breast cancer during her lifetime.1 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback